Be sure to check our sister interview main ratings news website

Advanced Oncotherapy Current EV significantly below cumulative investment to date (VIDEO)

Advanced Oncotherapy (LON:AVO) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joins DirectorsTalk.

Martin updates us on some of the recent developments at the company, explains why the share price is languishing, the demand for the project, shares his thoughts on the success of LIGHT and the company valuation.

Advanced Oncotherapy plc is a UK-based company focused on delivering a cost-effective proton-based radiotherapy solution called LIGHT. Based on ground-breaking technology developed and tested at world renowned CERN in Switzerland, the LIGHT system delivers an integrated proton radiotherapy system to treat cancer.

Read the full article
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    18th January 2023

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    29th September 2022

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    14th March 2022

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    15th November 2021

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    13th August 2021

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    16th December 2020

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    2nd July 2020

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    25th February 2020

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    17th February 2020

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    13th November 2019

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    11th November 2019

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked

    Hardman & Co

    ADVANCED ONCOTHERAPY Nearing the end goal

    15th August 2019

    AVO’s goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of technical milestones,

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.